Siegfried facility in Nantong receives operating approval
Siegfried received operating approval for Phase I of the production plant for active pharmaceutical ingredients at its new facility in Nantong, near Shanghai, China. Validation of the new plant commences with production in the pilot plant. Siegfried plans to produce first commercial batches in the second quarter of 2015.
Walter Kittl, Head Technical Operations at Siegfried: “Operating approval for Nantong represents an important milestone for us. We are convinced that this step will significantly support Siegfried’s growth and further improve our competitiveness.”
Construction of the new production facility in Nantong began mid-2013. It will provide a chemical-pharmaceutical capacity of 350 cubic meters. The technical concept of this facility is similar to that in Zofingen, which will be taken into operation in 2015, and thus - from a regulatory point of view - facilitate product transfer to and from Zofingen.
Once the facility is in full operation, Siegfried will employ some 300 employees in China. At present, 140 employees already work for Siegfried in Nantong.
Most read news
Organizations
Other news from the department manufacturing

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Harnessing jumping genes to advance gene-therapy cancer treatment - PlasmidFactory partnership to continue

New Start-up develops aquafarms for macroalgae - AWI and Carbonwave spin-off: Large algae simultaneously bind CO₂ and create raw materials for the chemical industry

Sepsis in Children: Improved Diagnosis Thanks to New Global Criteria - Researchers applied machine-learning methods to extrapolate from the data analysis evidence-based criteria for diagnosing
Prostate Cancer Survival Rates Improved Since Introduction of PSA Testing - Survival Rate for African American Men Now Comparable to Caucasians, The Journal of Urology Reports

Selvita appoints Dr. Nicolas D. Beuzen as Chief Scientific Officer and Member of the Management Board
